Stockscreener 앱 받기
9.71
4.24%
-0.43
전일 마감가:
$10.14
열려 있는:
$10.15
하루 거래량:
3.94M
Relative Volume:
1.80
시가총액:
$1.46B
수익:
-
순이익/손실:
$-738.82M
주가수익비율:
-1.3951
EPS:
-6.9602
순현금흐름:
$-610.15M
1주 성능:
+1.04%
1개월 성능:
-0.92%
6개월 성능:
+16.43%
1년 성능:
-57.07%
1일 변동 폭
$9.125
$10.78
1주일 범위
$8.95
$10.78
52주 변동 폭
$7.48
$22.22
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.71 | 1.53B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Canaccord Genuity | Buy |
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo Finance Australia
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
MSN Money - MSN
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Ltd files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) files shelf to register shares, debt and warrants - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83 - Moomoo
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biohaven (NYSE: BHVN) cuts Q1 2026 loss while funding late-stage drug pipeline - Stock Titan
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - ChartMill
Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan - Stock Titan
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio - simplywall.st
Biohaven Faces Catalyst-Rich 2H 2026 With Multiple Key Readouts Ahead - RTTNews
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Biohaven (NYSE: BHVN) receives 68,693 stock options award - Stock Titan
Director Julia P. Gregory awarded 68,693 Biohaven (BHVN) stock options - Stock Titan
(BHVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
Biohaven (NYSE:BHVN) Trading Up 5.2%Here's What Happened - MarketBeat
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap - simplywall.st
Biohaven (NYSE:BHVN) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline - simplywall.st
Biohaven Completes Enrollment for Obesity Drug Phase 2 Trial - HarianBasis.co
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN) - Insider Monkey
Spinocerebellar Ataxias Pipeline Advances Toward - openPR.com
Biohaven (NYSE:BHVN) Shares Down 5.7%What's Next? - MarketBeat
Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating - Insider Monkey
Responsive Playbooks and the BHVN Inflection - Stock Traders Daily
Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN
Biohaven (NYSE:BHVN) Upgraded by Wall Street Zen to Sell Rating - MarketBeat
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects - Sahm
Biohaven Receives 'Moderate Buy' Rating from Analysts - National Today
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha
Biohaven reports details on discovery of BHV-2100 - BioWorld News
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):